MedTrace Logo

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

NCT00176592 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2021-11-16

Study results available
· View outcomes & findings →

Summary

This is the first comparison of efficacy of Betaseron and Copaxone for treatment of relapsing forms of MS.

Conditions

Interventions

DRUG

Betaseron

Betaseron 250 micrograms injected SQ every other day

DRUG

Copaxone

Copaxone 20 mg injected SQ every day (glatiramer acetate)

Sponsors & Collaborators

  • University of Medicine and Dentistry of New Jersey

    lead OTHER

Principal Investigators

  • Stuart D Cook, MD · MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00176592 on ClinicalTrials.gov